Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Orbit ; 36(1): 6-12, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28145798

ABSTRACT

The traditional use of the Crawford tube for lacrimal intubation during dacryocystorhinostomy (DCR) carries several drawbacks. We describe the use of the STENTube for DCR intubation and detail its advantages. Retrospective, noncomparative, interventional case series; 313 patients with nasolacrimal duct obstruction (NLDO) underwent 339 DCRs (216 external, 123 endonasal) with the STENTube from January 2007 - June 2013 by 5 surgeons (RS, QN, TS, SB, TN) across 3 institutions (SUNY Downstate Medical Center, Texas Oculoplastics Consultants, and Moorfields Eye Hospital). Study outcome measures included patient demographics, surgical complications, and epiphora improvement/resolution. 206 (66%) females and 107 (34%) males had a mean age of 63 years (range 2-94 years). Distribution of diagnoses included: 314 complete idiopathic acquired NLDO, 20 partial idiopathic acquired NLDO, and 5 congenital complete NLDO. 316 (93%) were primary DCRs and 23 (7%) were revisions. Epiphora improved in 312 (92%) cases with 294 (86%) experiencing resolution with patent lacrimal irrigation at a mean last follow-up of 9.4 months. Twenty-eight (8%) patients experienced surgical complications with 16 (5%) experiencing tube prolapse, and 20 (6%) requiring re-operation. The STENTube represents a simple method for lacrimal intubation during external or endonasal DCR at a comparable cost to the Crawford tube. It allows for low prolapse rates without the need for additional endonasal fixation procedures, resulting in a simple and comfortable post-operative extraction without risk of lacrimal trauma. The STENTube is our preferred intubation technique during DCR, and should be considered by oculofacial surgeons performing DCR with intubation.


Subject(s)
Dacryocystorhinostomy/methods , Intubation , Lacrimal Duct Obstruction/therapy , Nasolacrimal Duct/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Humans , Male , Middle Aged , Postoperative Complications , Retrospective Studies , Therapeutic Irrigation , Treatment Outcome
2.
Ophthalmic Plast Reconstr Surg ; 30(6): 480-5, 2014.
Article in English | MEDLINE | ID: mdl-24841735

ABSTRACT

PURPOSE: Merkel cell carcinoma is a rare but potentially deadly cancer of the eyelid. To date, no studies have reported on clinical parameters at initial presentation of the eyelid tumor that may correlate with disease-free survival (DFS). The purpose of this study was to determine whether the American Joint Committee on Cancer (AJCC) T category for eyelid carcinoma correlates with metastasis and DFS in patients with Merkel cell carcinoma of the periocular region. METHODS: This is a retrospective cohort study from a tertiary referral cancer center. All consecutive patients treated for eyelid or periocular Merkel cell carcinoma between November 1, 1998, and November 1, 2012, were reviewed. The main outcome measures included AJCC T category for eyelid carcinoma and Merkel cell carcinoma at presentation, nodal metastasis at presentation, metastasis during follow up, and DFS. RESULTS: The study included 18 patients, 7 men and 11 women, with median age of 68.5 years. The AJCC T categories for both eyelid carcinoma and Merkel cell carcinoma were significantly correlated with DFS. Using the T categories for eyelid carcinoma, when TX and T2a were grouped into a single category and T2b and T3a into another category, the estimated DFS rate at 3 years was 100% for patients with TX or T2a lesions and 57% for patients with T2b or T3a lesions (p=0.0298). Four patients (22%) had lymph node metastasis at presentation. Presence of lymph node metastasis at presentation was the strongest single predictor of shorter DFS and an increased risk of metastasis during follow up (p=0.0222). CONCLUSIONS: The AJCC eyelid carcinoma T at presentation correlates with DFS in patients with Merkel cell carcinoma of the periocular region. The DFS rate at 3 years was significantly worse for patients with T2b or more extensive tumors by eyelid carcinoma T category. Presence of lymph node metastasis at presentation was predictive of shorter DFS and an increased risk of metastasis during follow up.


Subject(s)
Carcinoma, Merkel Cell/secondary , Eyelid Neoplasms/pathology , Skin Neoplasms/pathology , Aged , Aged, 80 and over , Carcinoma, Merkel Cell/classification , Carcinoma, Merkel Cell/mortality , Eyelid Neoplasms/classification , Eyelid Neoplasms/mortality , Female , Humans , Lymph Nodes/pathology , Lymphatic Metastasis , Male , Medical Oncology/organization & administration , Middle Aged , Neoplasm Staging , Retrospective Studies , Skin Neoplasms/classification , Skin Neoplasms/mortality , Survival Rate , United States
3.
Br J Ophthalmol ; 98(4): 498-501, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24429279

ABSTRACT

BACKGROUND/AIMS: Squamous cell carcinoma (SCC) of eyelid is the second most common cancer of the eyelid with the potential for nodal metastasis. The purpose of this report is to determine whether primary tumour size and 'T' designation in the American Joint Committee on Cancer (AJCC) staging system, 7th edition, correlate with the risk of regional nodal metastasis in patients with eyelid SCC. METHODS: Sixty-five consecutive patients with eyelid SCC treated by one ophthalmologist from March 1999 through July 2011 were included in this retrospective cohort study. Disease was staged using the AJCC 7th edition criteria based on clinical, pathological and radiographical data. Main outcome measures included regional lymph node metastasis at presentation, local recurrence, distant metastasis and survival at last follow-up. RESULTS: 40 men and 25 women had a median age of 67.0 years (range 41-89). TNM designations at presentation per the AJCC 7th edition were as follows: T1N0M0, 6 patients; T2aN0M0, 11 patients; T2bN0M0, 17 patients; T2bN1M0, 2 patients; T3aN0M0, 22 patients; T3bN0M0, 2 patients; T3bN1M0, 1 patient; T4N0M0, 3 patients; and T4N1M0, 1 patient. Median follow-up was 27 months (range 1-150). Four patients had nodal metastasis at presentation. Two of these four patients had T2bN1M0 disease, one had T3bN1M0 disease and one had T4N1M0 disease. Two patients, with T3aN0M0 and T4N0M0 tumours, respectively, at presentation, developed lymph node metastasis at 2 weeks and 8.4 months, respectively, after tumour excision. The four patients who had lymph node metastases at presentation and the two who developed lymph node metastases during follow-up had tumours ≥18 mm in greatest dimension or T2b or higher at presentation. Seven local recurrences were observed during follow-up. Two-year and 3-year recurrence-free survival rates were 93% (95% CI 80% to 98%) and 82% (95% CI 63% to 92%), respectively. No distant metastasis or tumour-related death was observed during follow-up. The 2-year and 3-year disease-free survival rates were 90% (95% CI 77% to 96%) and 79% (95% CI 61% to 89%), respectively. CONCLUSIONS: Regional nodal metastases were observed among patients who presented with tumours >T2b. Tumour size and the AJCC TNM designations correlate with metastasis and should be reported more often for eyelid SCCs to allow comparisons across centres.


Subject(s)
Carcinoma, Squamous Cell/secondary , Eyelid Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/classification , Carcinoma, Squamous Cell/mortality , Eyelid Neoplasms/classification , Eyelid Neoplasms/mortality , Female , Follow-Up Studies , Humans , Lymph Nodes/pathology , Lymphatic Metastasis , Male , Medical Oncology/organization & administration , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Neoplasm Staging , Survival Rate , United States
4.
Leuk Lymphoma ; 55(5): 1013-7, 2014 May.
Article in English | MEDLINE | ID: mdl-23879202

ABSTRACT

Abstract The objective of this study was to assess the value of magnetic resonance imaging (MRI) of the orbit for conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma. The yield of other staging tests at baseline were also evaluated. Twenty-one consecutive patients treated for conjunctival MALT lymphoma were retrospectively studied. Lymphoma was staged according to both the Ann Arbor system and the seventh edition of the AJCC [American Joint Committee on Cancer] cancer staging manual. Findings on MRI of the orbit, whole-body positron emission tomography/computed tomography (PET/CT), CT of the chest/abdomen/pelvis, bone marrow (BM) biopsy and gastrointestinal (GI) endoscopy were recorded. Seventeen patients had orbital MRI. Fourteen of 17 patients (82%) with obvious conjunctival MALT lymphoma on clinical examination had a negative MRI scan. Only three patients had subtle conjunctival enhancement on orbital MRI. Ann Arbor stage at presentation was as follows: stage IE (15 patients), stage IIE (two patients) and stage IV (four patients). Eighteen of 21 patients had total-body PET/CT; four patients (22%) had hypermetabolic activity evident on PET scan. All 21 patients had bilateral BM biopsies. Fifteen of 21 patients (71%) had GI endoscopy. None of the patients had a positive BM biopsy or findings on GI endoscopy. Our data suggest that orbital MRI has a very low yield for identification of conjunctival MALT lymphoma. Clinical examination is critical in diagnosing and assessing treatment response in conjunctival MALT lymphoma. The yield for GI endoscopy and BM biopsy may also be low in staging of conjunctival MALT lymphoma.


Subject(s)
Conjunctiva/pathology , Diagnostic Tests, Routine , Lymphoma, B-Cell, Marginal Zone/diagnosis , Magnetic Resonance Imaging , Adult , Aged , Biopsy , Bone Marrow/pathology , Combined Modality Therapy , Endoscopy, Gastrointestinal , Female , Follow-Up Studies , Humans , Lymphoma, B-Cell, Marginal Zone/pathology , Lymphoma, B-Cell, Marginal Zone/therapy , Male , Middle Aged , Neoplasm Staging , Positron-Emission Tomography , Tomography, X-Ray Computed , Treatment Outcome , Young Adult
5.
Digit J Ophthalmol ; 20(3): 35-40, 2014.
Article in English | MEDLINE | ID: mdl-27843414

ABSTRACT

PURPOSE: To describe 3 cases of primary orbital melanoma associated with either known or subsequently discovered cellular blue nevus. METHODS: The clinical records and surgical specimens of 3 patients who underwent orbital exenteration for primary orbital melanoma and who had a cellular blue nevus diagnosed before or after detection of the melanoma were retrospectively reviewed. RESULTS: All 3 patients presented with signs and symptoms of an orbital mass. Subsequent biopsy revealed invasive melanoma. One patient had a known history of congenital cellular blue nevus of the eyelid from which the orbital melanoma originated. The other 2 patients had no known history of cutaneous pigmentation or blue nevus. In these 2 patients, the cellular blue nevus was detected on pathologic review of the orbital exenteration specimen (1 patient) or surgical biopsy specimen (1 patient). All 3 patients underwent total body positron emission tomography/computed tomography, and in all 3 results were negative for other sites of disease involvement. In the 2 patients without a previously known nevus a total body skin check was negative for other primary melanoma lesions. All 3 patients underwent orbital exenteration followed by postoperative radiation therapy. CONCLUSIONS: Thorough evaluation of biopsy specimens of "primary" orbital melanoma is warranted to ensure identification of any associated blue nevus because blue nevi are precursor lesions for orbital melanoma, and the presence of a blue nevus would support a primary orbital melanoma rather than a metastatic lesion. Patients with a known blue nevus of the periocular skin and ocular adnexa should be monitored closely for signs of malignant transformation.


Subject(s)
Melanoma/pathology , Neoplasms, Multiple Primary/pathology , Nevus, Blue/pathology , Orbital Neoplasms/pathology , Adult , Child , Female , Humans , Middle Aged
6.
Ophthalmic Plast Reconstr Surg ; 29(6): 454-7, 2013.
Article in English | MEDLINE | ID: mdl-24195987

ABSTRACT

PURPOSE: To determine the rates of globe-sparing treatment and useful final visual function in patients with primary lacrimal sac/nasolacrimal duct carcinomas treated with multidisciplinary therapy. METHODS: The medical records of 14 patients with primary lacrimal sac/nasolacrimal duct carcinoma treated at 1 institution were retrospectively reviewed. RESULTS: The patients were 9 men and 5 women; the median age at diagnosis was 58.5 years (range, 45-73 years). Seven patients presented with epiphora, 7 with a palpable mass in the inferomedial orbit, and 2 with dacryocystitis. In 3 patients, the diagnosis of cancer was not considered until during or after dacryocystorhinostomy. Seven patients had squamous cell carcinoma, 2 transitional cell carcinoma, 2 adenoid cystic carcinoma, and 1 each adenocarcinoma, poorly differentiated carcinoma, and inverted papilloma with carcinoma in situ transformation. Nine patients underwent surgical resection of the lacrimal sac and nasolacrimal duct and resection of the medial upper and lower eyelids, including canaliculi, partial ethmoidectomy, and medial maxillectomy. One patient underwent lacrimal sac biopsy only as another primary malignancy was discovered during the work-up for systemic disease. Four patients underwent orbital exenteration because of extensive involvement of the orbital soft tissue. Radiotherapy was recommended for 13 patients; in 1 patient, radiotherapy was not recommended because the patient had an inverted papilloma with carcinoma in situ transformation that was completely excised. The median radiation dose was 60 Gy. Eight patients received chemotherapy either concurrent with radiation therapy (5 patients), as neoadjuvant treatment (1 patient), or for progressive or metastatic disease (3 patients). The median follow-up time was 27 months (range, 6-96 months). In 10 patients, the globe was spared. In 9 of these 10 patients, visual acuity was the same as at baseline or better than 20/40 at last follow up. CONCLUSIONS: With multidisciplinary therapy, the eye can be spared and reasonable visual function can be preserved in most patients with primary lacrimal sac/nasolacrimal duct carcinomas.


Subject(s)
Carcinoma/therapy , Eye Neoplasms/therapy , Lacrimal Apparatus Diseases/therapy , Nose Neoplasms/therapy , Aged , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Male , Middle Aged , Nasolacrimal Duct , Orbit Evisceration , Radiation Dosage , Retrospective Studies , Visual Acuity
7.
Ophthalmic Plast Reconstr Surg ; 29(6): e143-6, 2013.
Article in English | MEDLINE | ID: mdl-23446295

ABSTRACT

Primary cutaneous adenoid cystic carcinoma of the eyelid is an extremely rare entity with the propensity to recur locally, spread to regional lymph nodes, and invade perineural spaces. Of the 8 cases previously reported in the literature, only 2 were noted to be associated with perineural invasion, and neither of these was treated with radiation therapy. The authors report the case of a 35-year-old woman who presented with a progressively enlarging left lower eyelid lesion. An excisional biopsy with wide margins revealed a diagnosis of primary adenoid cystic carcinoma of the eyelid with perineural invasion. Because of the high risk of recurrence associated with perineural invasion, the patient received postoperative adjuvant radiation in the form of 50 Gy relative biological effectiveness of proton beam therapy to the postoperative tumor bed and to the infraorbital nerve tracking back to the apex of the orbit, followed by a 10-Gy boost to the lower eyelid tumor bed with orthovoltage x-rays.


Subject(s)
Carcinoma, Adenoid Cystic/therapy , Eyelid Neoplasms/therapy , Proton Therapy , Adult , Carcinoma, Adenoid Cystic/pathology , Eyelid Neoplasms/pathology , Female , Humans , Neoplasm Invasiveness/pathology , Neoplasm Invasiveness/prevention & control , Postoperative Period , Radiation Dosage , Radiotherapy, Adjuvant , Treatment Outcome
8.
Ophthalmic Plast Reconstr Surg ; 28(3): 208-12, 2012.
Article in English | MEDLINE | ID: mdl-22581085

ABSTRACT

PURPOSE: High-dose radiotherapy can cause contracture of the anophthalmic socket, but the incidence of this complication in patients with enucleation for uveal melanoma has not been reported previously. The authors reviewed the surgical management and outcomes in terms of successful prosthesis wear in patients with severe contracture of the anophthalmic socket treated with high-dose radiotherapy for high-risk uveal melanoma, and they estimated the relative risk of this complication. METHODS: The medical records of all consecutive patients enrolled in a prospective uveal-melanoma tissue-banking protocol at the authors' institution who underwent enucleation between January 2003 and December 2010 were reviewed. Patients who underwent adjuvant radiotherapy of the enucleated socket were further studied. RESULTS: Of the 68 patients enrolled in the prospective tissue-banking protocol, 12 had high-risk histologic features (e.g., extrascleral spread or vortex vein invasion) and were treated with 60 Gy of external beam radiotherapy after enucleation. Five of these patients (41.7%) experienced severe socket contracture precluding prosthesis wear. The median time to onset of contracture following completion of radiotherapy was 20 months. Three patients underwent surgery, which entailed scar tissue release, oral mucous membrane grafting, and socket reconstruction; 2 patients declined surgery. All 3 patients who had surgery experienced significant improvement of socket contracture that enabled patients to wear a prosthesis again. CONCLUSION: High-dose radiotherapy after enucleation in patients with uveal melanoma caused severe socket contracture and inability to wear a prosthesis in approximately 40% of patients. Surgical repair of the contracted socket using oral mucous membrane grafting can allow resumption of prosthesis wear.


Subject(s)
Eye Enucleation , Melanoma/surgery , Orbit/radiation effects , Orbital Diseases/surgery , Radiation Injuries/surgery , Radiotherapy, High-Energy/adverse effects , Uveal Neoplasms/surgery , Eye, Artificial , Humans , Mouth Mucosa/transplantation , Ophthalmologic Surgical Procedures , Orbital Diseases/etiology , Orbital Diseases/mortality , Orbital Implants , Postoperative Care , Prospective Studies , Radiation Injuries/etiology , Radiation Injuries/mortality , Radiotherapy Dosage , Plastic Surgery Procedures , Survival Rate
9.
Orbit ; 31(4): 264-6, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22571512

ABSTRACT

Orbital malignancy can mimic thyroid associated orbitopathy (TAO) due to overlap of clinical and radiographic findings, which include proptosis, extraocular muscle (EOM) enlargement on imaging, and EOM restriction with diplopia. We report a case of primary orbital liposarcoma masquerading as TAO which required exenteration.


Subject(s)
Diagnostic Errors , Graves Ophthalmopathy/diagnosis , Liposarcoma/diagnosis , Orbital Neoplasms/diagnosis , Diagnosis, Differential , Diplopia/diagnosis , Exophthalmos/diagnosis , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Oculomotor Muscles/diagnostic imaging , Tomography, X-Ray Computed , Visual Acuity
10.
Ophthalmic Plast Reconstr Surg ; 28(3): 196-8, 2012.
Article in English | MEDLINE | ID: mdl-22460683

ABSTRACT

PURPOSE: To evaluate the outcomes of dacryocystorhinostomy (DCR) in patients with head and neck cancer treated with high-dose radiation therapy. METHODS: The clinical records of 43 consecutive patients with head and neck cancer who underwent DCR after high-dose external beam radiation therapy plus ablative surgery and/or chemotherapy between December 2001 and April 2011 were retrospectively reviewed. RESULTS: There were 23 men and 20 women. The median age was 56 years (range, 2-92 years). Thirty-one patients were Caucasian, 6 Hispanic, 4 Asian, and 2 African American. Thirty patients (70%) presented with epiphora, 3 (7%) with dacryocystitis, and 10 (23%) with both epiphora and dacryocystitis. Symptoms were unilateral in 34 patients (79%) and bilateral in 9 patients (21%). The most common primary cancer diagnoses were squamous cell carcinoma (n = 14), sarcoma (n = 8), adenoid cystic carcinoma (n = 4), and basal cell carcinoma (n = 4). The most common primary tumor locations were the sinonasal cavity (n = 16), maxillary sinus (n = 9), palate (n = 3), and ethmoid sinus (n = 3). Thirty-seven patients (43 eyes) had DCR with silicone tube placement, and 6 patients (7 eyes) had DCR with Pyrex glass tube placement. Following DCR, 31 patients (72%) had resolution of their symptoms, and 12 patients (28%), 9 with silicone tubes and 3 with Pyrex glass tubes, had persistent or recurrent epiphora (DCR failure). The most common reason for failure was significant residual canalicular and nasal mucosal scar tissue. Eight of these 12 patients underwent additional surgery, most commonly with placement of a Pyrex glass tube. Seven (35%) of the 20 patients who underwent DCR less than 12 months after radiation therapy and 5 (21%) of the 23 patients who underwent DCR at least 12 months after radiation therapy had recurrent symptoms. CONCLUSIONS: Dacryocystorhinostomy in patients with head and neck cancer previously treated with high-dose radiation therapy is generally successful, especially when delayed until at least 12 months after the completion of radiation therapy. A common reason for DCR failure after high-dose radiation therapy is severe canalicular and nasal mucosal scarring.


Subject(s)
Dacryocystorhinostomy , Head and Neck Neoplasms/radiotherapy , Nasolacrimal Duct/surgery , Radiation Injuries/surgery , Radiotherapy, High-Energy/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Dose Fractionation, Radiation , Female , Follow-Up Studies , Head and Neck Neoplasms/pathology , Humans , Lacrimal Duct Obstruction/etiology , Male , Middle Aged , Nasolacrimal Duct/radiation effects , Radiation Injuries/etiology , Radiotherapy Dosage , Retrospective Studies , Treatment Outcome , Young Adult
11.
Ophthalmology ; 119(5): 1078-82, 2012 May.
Article in English | MEDLINE | ID: mdl-22330966

ABSTRACT

PURPOSE: To determine whether T category of the American Joint Committee on Cancer (AJCC) TNM staging system for eyelid carcinoma, 7th edition, correlates with lymph node metastasis, distant metastasis, and survival in patients with sebaceous carcinoma of the eyelid. DESIGN: Retrospective, cohort study. PARTICIPANTS: Fifty consecutive patients treated by 1 author (BE) for eyelid sebaceous carcinoma between May 1999 and August 2010. METHODS: Each tumor was staged according to the AJCC 7th edition TNM criteria. The Kaplan-Meier method was used to determine associations between disease-specific survival and (1) T category at presentation, (2) lymph node metastasis, and (3) distant metastasis. MAIN OUTCOME MEASURES: T category at presentation, nodal metastasis, survival. RESULTS: The study included 37 women and 13 men (median age, 68.5 years; range, 44-86 years). Forty-four patients were white, 5 were Hispanic, and 1 was Asian. TNM designations were TXN0M0, 7 patients; T1N0M0, 4 patients; T2aN0M0, 12 patients; T2bN0M0, 11 patients; T2bN1M0, 2 patients; T2bN1M1, 1 patient; T3aN0M0, 2 patients; T3aN1M0, 5 patients; T3bN0M0, 1 patient; T3bN1M0, 1 patient; T3bN0M1, 2 patients; T4N0M0, 1 patient; and T4N0M1, 1 patient. T category at presentation was significantly associated with lymph node metastasis (P = 0.0079). No tumors with T category better than T2b or smaller than 9 mm in greatest dimension were associated with nodal metastasis. Five patients (10%) died of disease during follow-up. Their TNM designations were T2bN1M1, 1 patient; T3bN0M1, 2 patients; T4N0M0, 1 patient; and T4N0M1, 1 patient. No tumors smaller than 12 mm in greatest dimension were associated with distant metastasis or death. T category was significantly associated with disease-specific survival (P = 0.0009). Disease-specific survival was poorer among patients with T category of T3a or worse (P = 0.035). CONCLUSIONS: T category in the 7th edition of the AJCC TNM staging system for eyelid carcinoma correlates with outcomes in patients with sebaceous carcinoma of eyelid. On the basis of the present findings, it seems reasonable to recommend sentinel lymph node biopsy or at least strict regional lymph node surveillance for patients with eyelid sebaceous carcinoma with tumors of T category T2b or worse or 10 mm or more in greatest dimension.


Subject(s)
Adenocarcinoma, Sebaceous/secondary , Eyelid Neoplasms/pathology , Sebaceous Gland Neoplasms/pathology , Adenocarcinoma, Sebaceous/classification , Adenocarcinoma, Sebaceous/mortality , Adult , Aged , Aged, 80 and over , Eyelid Neoplasms/classification , Eyelid Neoplasms/mortality , Female , Humans , Lymph Nodes/pathology , Lymphatic Metastasis , Male , Medical Oncology/organization & administration , Medical Oncology/standards , Middle Aged , Neoplasm Staging , Retrospective Studies , Sebaceous Gland Neoplasms/classification , Sebaceous Gland Neoplasms/mortality , Sentinel Lymph Node Biopsy , Survival Rate , United States
12.
Ophthalmic Plast Reconstr Surg ; 28(4): e82-5, 2012.
Article in English | MEDLINE | ID: mdl-22082592

ABSTRACT

Idiopathic orbital inflammation is a common cause of acute orbital signs and symptoms. It is typically confined to the bony orbit; however, it can rarely involve contiguous structures with or without lytic change raising clinical suspicion for malignancy. Three cases of idiopathic inflammation of the orbit that affected adjacent structures are reported here; 2 cases had maxillary sinus involvement, while a third had extension in the temporal fossa.


Subject(s)
Dacryocystitis/complications , Maxillary Sinusitis/complications , Orbital Myositis/complications , Adolescent , Adult , Biopsy , Child, Preschool , Dacryocystitis/diagnostic imaging , Dacryocystitis/drug therapy , Drug Therapy, Combination , Female , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Male , Maxillary Sinusitis/diagnostic imaging , Maxillary Sinusitis/drug therapy , Methotrexate/therapeutic use , Orbital Myositis/diagnostic imaging , Orbital Myositis/drug therapy , Prednisone/therapeutic use , Tomography, X-Ray Computed , Visual Acuity
13.
Ophthalmology ; 118(11): 2307-8; author rpely 3208-9, 2011 Nov.
Article in English | MEDLINE | ID: mdl-22047898
16.
Ophthalmology ; 115(1): 94-8, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18166406

ABSTRACT

PURPOSE: To assess the cost-effectiveness of treating ocular hypertension (OHT) in the United States. DESIGN: A Markov model was constructed to perform a cost-effectiveness analysis. PARTICIPANTS: Patients with OHT. METHODS: The health states considered were stable OHT and glaucoma. Practice patterns for the model were derived from the Ocular Hypertension Treatment Study (OHTS), and transition probabilities were derived from previous literature. Specific unit costs used for medications, patient visits, and diagnostic and therapeutic procedures were obtained from Blue Cross/Blue Shield. The time horizon was 5 years. Costs were discounted at 3% per annum. MAIN OUTCOME MEASURE: Long-term cost effectiveness of treating OHT to prevent the development of glaucoma. RESULTS: The incremental cost-effectiveness ratio (ICER) for all OHT patients to prevent 1 case from progressing to primary open-angle glaucoma was $89,072. However, the minimally cost-effective ICER level after adjustment for risk factors identified by multivariate analysis in the OHTS were: 20 years above the average of 56 years, ICER of $45,155; 4 mmHg above the average pressure of 25 mmHg, ICER of $46,748; 40 microm less than the average central corneal thickness of 573 mum, ICER of $36,683; and a vertical cup-to-disc ratio of 0.2 wider than the average of 0.4, ICER of $35,633. CONCLUSIONS: Based on the results and practice patterns of the OHTS, treating all OHT patients seems not to be cost-effective. However, treating selective OHT patients with risk factors identified in the OHTS, for example, advancing age, higher pressures, thinner central corneal thickness, and wider vertical cup-to-disc ratios, does seem to be cost-effective for preventing the onset of glaucomatous damage.


Subject(s)
Health Care Costs , Ocular Hypertension/economics , Ocular Hypertension/therapy , Aged , Antihypertensive Agents/economics , Antihypertensive Agents/therapeutic use , Cost-Benefit Analysis , Decision Support Techniques , Glaucoma, Open-Angle/prevention & control , Health Services Research , Humans , Insurance, Health/statistics & numerical data , Intraocular Pressure , Markov Chains , Middle Aged , Quality of Life , Quality-Adjusted Life Years , Risk Factors , Trabeculectomy/economics , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...